Ron Morena

Ron Morena is a skilled professional with over 30 years of experience in the biopharmaceutical industry. Ron has contributed significantly to the development and advancement of various monoclonal antibodies, including Zevalin™, which was the first radiolabeled monoclonal antibody approved by the FDA for cancer therapy. Ron has a strong background in analytical bioassay and has successfully navigated FDA Preapproval Inspections. Ron is a Subject Matter Expert in Biacore related activities and has been actively involved in multiple Biological License Applications. Overall, Ron is a valuable asset with a proven track record of successful project management and scientific contributions.